Literature DB >> 32213028

Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.

Sophia Heinrich1, Martin Sprinzl1, Irene Schmidtmann1, Elena Heil1, Sandra Koch1, Carolin Czauderna1, Bernd Heinrich1, Laurence Philippe P Diggs2, Marcus-Alexander Wörns1, Roman Kloeckner3, Peter R Galle1, Jens U Marquardt1, Arndt Weinmann1.   

Abstract

BACKGROUND AND AIM: The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly used to classify hepatocellular carcinoma (HCC) patients. However, other staging classification schemes have been proposed. We aimed to compare the prognostic accuracy of the Hong Kong Liver Cancer Staging (HKLC), the Model to Estimate Survival for HCC (MESH), and the BCLC staging systems using a Western cohort of HCC patients.
METHODS: We retrospectively analyzed 918 patients diagnosed with HCC treated at the University Medical Center of Mainz between 2005 and 2014. We compared the predictive power of survival time of the BCLC, HKLC, and MESH. Predictive ability was tested using the integrated Brier score (IBS) and Harrell's C index.
RESULTS: Kaplan-Meier analyses showed significant differences in survival between stages defined by the BCLC, HKLC, and MESH. The HKLC classification demonstrated a more robust classification concordance and lower prediction error compared to the BCLC and MESH. In addition, we found that the BCLC offers superior predictive ability to the MESH in the first four years, whereas the MESH is superior for long-term predictions.
CONCLUSION: Our analyses confirm the prognostic value of three different HCC scoring systems. When compared, the HKLC provides superior prognostication ability.

Entities:  

Keywords:  BCLC; HKLC; MESH; Staging; hepatocellular carcinoma; prognosis; survival

Mesh:

Substances:

Year:  2020        PMID: 32213028      PMCID: PMC7226688          DOI: 10.1177/2050640620904524

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  33 in total

1.  Genomic decoding of hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2006-10       Impact factor: 22.682

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort.

Authors:  Neehar D Parikh; Steve Scaglione; Yumeng Li; Corey Powell; Olutola A Yerokun; Pauline Devlin; Shaham Mumtaz; Sahil Mittal; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-10-05       Impact factor: 11.382

4.  Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.

Authors:  Jae Ho Sohn; Rafael Duran; Yan Zhao; Florian Fleckenstein; Julius Chapiro; Sonia Sahu; Rüdiger E Schernthaner; Tianchen Qian; Howard Lee; Li Zhao; James Hamilton; Constantine Frangakis; MingDe Lin; Riad Salem; Jean-Francois Geschwind
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-12       Impact factor: 11.382

5.  Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.

Authors:  Stephen L Chan; Frankie Mo; Philip Johnson; Leung Li; Nelson Tang; Herbert Loong; Anthony W H Chan; Jane Koh; Anthony T C Chan; Winnie Yeo
Journal:  J Gastroenterol Hepatol       Date:  2015-10       Impact factor: 4.029

Review 6.  The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma.

Authors:  P J Johnson
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

7.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

8.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

9.  Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Yi-Hsiang Huang; Chien-Wei Su; Fa-Yauh Lee; Han-Chieh Lin; Teh-Ia Huo
Journal:  Eur J Cancer       Date:  2016-05-31       Impact factor: 9.162

10.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.

Authors:  Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S Orsini; Morris Sherman
Journal:  Liver Int       Date:  2015-03-25       Impact factor: 5.828

View more
  2 in total

1.  Predictive scores for hepatocellular carcinoma: a race with no winners?

Authors:  Raffaella Tortora; Marco Guarracino; Giovan Giuseppe Di Costanzo
Journal:  Ann Transl Med       Date:  2020-10

Review 2.  How to Treat Hepatocellular Carcinoma in Elderly Patients.

Authors:  Piera Federico; Emilio Francesco Giunta; Annalisa Pappalardo; Andrea Tufo; Gianpaolo Marte; Laura Attademo; Antonietta Fabbrocini; Angelica Petrillo; Bruno Daniele
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.